These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 11816246)

  • 21. Does enteric-coated aspirin result in a lower incidence of gastrointestinal complications compared to normal aspirin?
    Walker J; Robinson J; Stewart J; Jacob S
    Interact Cardiovasc Thorac Surg; 2007 Aug; 6(4):519-22. PubMed ID: 17669925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gastric injury caused by low-dose aspirin therapy in consecutive Japanese patients: a prospective study.
    Fukuda S; Hosaka S; Ozawa N; Akita S; Kashima T; Kimura S; Akiyama J; Mizoue T
    Gen Thorac Cardiovasc Surg; 2012 May; 60(5):275-9. PubMed ID: 22453536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concomitant use of buffered and enteric-coated low-dose aspirin products and antisecretory drugs.
    Takada M; Fukumoto K; Shibakawa M
    J Clin Pharm Ther; 2004 Apr; 29(2):183-7. PubMed ID: 15068408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gastric safety and enteric-coated aspirin.
    Petroski D
    Lancet; 1997 Feb; 349(9049):430-1. PubMed ID: 9033489
    [No Abstract]   [Full Text] [Related]  

  • 25. Reduction in gastric mucosal hemorrhage and ulceration with chronic high-level dosing of enteric-coated aspirin granules two and four times a day.
    Lanza FL; Rack MF; Wagner GS; Balm TK
    Dig Dis Sci; 1985 Jun; 30(6):509-12. PubMed ID: 3873326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-dose aspirin may or may not damage the gastric mucosa.
    Graham DY; Moon N
    Gastroenterology; 1999 Dec; 117(6):1505. PubMed ID: 10610340
    [No Abstract]   [Full Text] [Related]  

  • 27. [Enteric-coated aspirin does not reduce the risk of gastrointestinal side effects].
    Haastrup P; Jarbøl DE
    Ugeskr Laeger; 2014 Apr; 176(9):. PubMed ID: 25096559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Mucoprotective drugs and aspirin-induced gastric injury].
    Sugiyama T; Yamawaki H
    Nihon Rinsho; 2010 Nov; 68(11):2077-82. PubMed ID: 21061536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NSAID-induced gastric mucosal damage.
    Semble EL; Wu WC
    Am Fam Physician; 1987 Jun; 35(6):101-8. PubMed ID: 3332745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gastric safety and enteric-coated aspirin.
    Sullivan JL
    Lancet; 1997 Feb; 349(9049):431-2. PubMed ID: 9033491
    [No Abstract]   [Full Text] [Related]  

  • 31. Correlation between Helicobacter pylori infection and low-dose aspirin use on damage of the upper gastrointestinal tract.
    Fukuzawa M; Kawai T; Watanabe M; Tomiyama H; Yamashina A; Moriyasu F
    J Gastroenterol Hepatol; 2012 Apr; 27 Suppl 3():76-81. PubMed ID: 22486876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Risk factors for gastrointestinal bleeding associated with low-dose aspirin].
    Sibilia J; Ravaud P; Marck G
    Presse Med; 2003 Nov; 32(37 Pt 2):S9-16. PubMed ID: 14763349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa.
    Lanza FL; Royer GL; Nelson RS
    N Engl J Med; 1980 Jul; 303(3):136-8. PubMed ID: 6966762
    [No Abstract]   [Full Text] [Related]  

  • 34. Risk and preventive factors of low-dose aspirin-induced gastroduodenal injuries: a comprehensive review.
    Shiotani A; Manabe N; Kamada T; Fujimura Y; Sakakibara T; Haruma K
    J Gastroenterol Hepatol; 2012 Apr; 27 Suppl 3():8-12. PubMed ID: 22486865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protection of human gastric mucosa against aspirin-enteric coating or dose reduction?
    Cole AT; Hudson N; Liew LC; Murray FE; Hawkey CJ; Heptinstall S
    Aliment Pharmacol Ther; 1999 Feb; 13(2):187-93. PubMed ID: 10102949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The epidemiology of the gastroduodenal damage induced by aspirin and other nonsteroidal anti-inflammatory drugs].
    Dobrilla G; Benvenuti S; de Guelmi A
    Recenti Prog Med; 1997 May; 88(5):202-11. PubMed ID: 9244954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minimization of gastric damage with enteric-coated aspirin granules compared to buffered aspirin.
    Anslow JA; Balm TK; Hooper JW; Szego P; Wagner GS
    Pharmacology; 1985; 30(1):40-4. PubMed ID: 3975255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor.
    Goldstein JL; Lowry SC; Lanza FL; Schwartz HI; Dodge WE
    Aliment Pharmacol Ther; 2006 May; 23(10):1489-98. PubMed ID: 16669964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of enteric-coated aspirin granules with plain and buffered aspirin: a report of two studies.
    Petroski D
    Am J Gastroenterol; 1986 Jan; 81(1):26-8. PubMed ID: 3942122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis.
    Hawthorne AB; Mahida YR; Cole AT; Hawkey CJ
    Br J Clin Pharmacol; 1991 Jul; 32(1):77-83. PubMed ID: 1888645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.